Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam for Neonatal Seizures in Hypoxic-Ischemic Encephalopathy
NCT02229123Phase 2Completed
- Sponsor
- University Hospital Tours
- Start
- Feb 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of levetiracetam in neonatal seizures, sponsored by University Hospital Tours. Primary endpoints: Levetiracetam Efficacy on EEG recording at 4.25 hours, Levetiracetam Short-Term Toxicity at 6 days and 1 more. Started Feb 2018; status: completed.
02
Drugs
levetiracetam
03
Conditions
neonatal seizures
Beyond the preview
Go deeper on NCT02229123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229123.